This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
GSK (GSK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants
by Zacks Equity Research
Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $34.51, moving -0.06% from the previous trading session.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $34.80, moving +0.87% from the previous trading session.
3 Healthcare Stocks to Buy Amid Market Volatility
by Abhinab Dasgupta
Patterson (PDCO), Perrigo (PRGO) and GSK are three healthcare stocks that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.
Why GSK (GSK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $33.81, marking a -0.82% move from the previous day.
GSK vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine
by Zacks Equity Research
Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DNL
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $35.29 in the latest trading session, marking a -0.98% move from the prior day.
GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.
GSK (GSK) Stock Moves -0.3%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $36.27 in the latest trading session, marking a -0.3% move from the prior day.
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how GSK (GSK) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.
Company News for Jun 26, 2023
by Zacks Equity Research
Companies in The News Are: KMX, GS, SBUX, GSK.
Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More
by Zacks Equity Research
Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.
GSK (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $34.62, moving -1.51% from the previous trading session.
GSK vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
GSK Announces Extension of FDA Review for Rare Blood Therapy
by Zacks Equity Research
GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $34.64 in the latest trading session, marking a +0.73% move from the prior day.
FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody
by Zacks Equity Research
The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.
Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More
by Zacks Equity Research
Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.
GSK (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $34.36, moving -0.75% from the previous trading session.